Stock listing
NVCT Stock Price, News, Filings & Events — Nuvectis Pharma, Inc.
Selected listing: NVCT · NASDAQ · USD · US
This page tracks Nuvectis Pharma, Inc.'s NVCT:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NVCT:NASDAQ. NVCT:NASDAQ is the stock-level entry point for investors researching Nuvectis Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Nuvectis Pharma, Inc. is a public company traded under the ticker NVCT in the American market. The company has a market capitalization of approximately $608.76 million. Nuvectis focuses on developing innovative therapies for cancer treatment.
- Ticker
- NVCT:NASDAQ
- Asset type
- Stock
- Market cap
- $783.1M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Nuvectis Pharma, Inc. NVCT:NASDAQ stock context
This page tracks Nuvectis Pharma, Inc.'s NVCT:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NVCT:NASDAQ. NVCT:NASDAQ is the stock-level entry point for investors researching Nuvectis Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Nuvectis Pharma, Inc. is a public company traded under the ticker NVCT in the American market. The company has a market capitalization of approximately $608.76 million. Nuvectis focuses on developing innovative therapies for cancer treatment.
Latest news from Nuvectis Pharma, Inc.
Nuvectis Pharma To Participate in Upcoming Investor Conferences
September 3, 2026
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
August 4, 2026
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhi...
July 23, 2026
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with P...
July 23, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
June 29, 2026
Research Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. investor report
Review AI stock analysis and investor report context for NVCT:NASDAQ.
Nuvectis Pharma, Inc. company profile
View the public company page for Nuvectis Pharma, Inc. on 6ix.
Nuvectis Pharma, Inc. news
Read company news and market updates connected to Nuvectis Pharma, Inc..
Nuvectis Pharma, Inc. investor events
Find investor webinars, events, and replay context for Nuvectis Pharma, Inc..